|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
Valuation Estimation |
EPS (Current/Estimated)
-0.50/2.65
|
Enterprise Value
36.60B
|
Balance Sheet |
Book Value Per Share
6.63
|
Cash Flow |
Cash Flow Yield
0.08
|
Income Statement |
Total Revenue
15.85B
|
Operating Revenue Per Share
13.26
|
Industry Comparison
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
Quotes are at least 15-min delayed:2024/05/11 23:08 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
|
|||
Teva Pharmaceutical Industries, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the U.S. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a U.S.-based generic andspecialty drug distributor. |